SMC 'yes' for Roche's RoActemra, 'no' for Gilead's Cayston Pharma Times The group concluded that RoActemra was superior to placebo in reducing disease activity and fever in patients with persistent forms of the illness despite having received previous treatment with NSAIDs and corticosteroids, and acknowledged the ... |
